HLB Life Science Balance Sheet Health
Financial Health criteria checks 5/6
HLB Life Science has a total shareholder equity of ₩359.4B and total debt of ₩118.7B, which brings its debt-to-equity ratio to 33%. Its total assets and total liabilities are ₩493.7B and ₩134.3B respectively.
Key information
33.0%
Debt to equity ratio
₩118.74b
Debt
| Interest coverage ratio | n/a |
| Cash | ₩71.92b |
| Equity | ₩359.37b |
| Total liabilities | ₩134.28b |
| Total assets | ₩493.65b |
Recent financial health updates
HLB Life Science (KOSDAQ:067630) Has Debt But No Earnings; Should You Worry?
Apr 12
Is HLB Life Science (KOSDAQ:067630) A Risky Investment?
Jan 10Recent updates
HLB Life Science Co., Ltd.'s (KOSDAQ:067630) Popularity With Investors Under Threat As Stock Sinks 26%
Oct 24What HLB Life Science Co., Ltd.'s (KOSDAQ:067630) P/S Is Not Telling You
Aug 30HLB Life Science (KOSDAQ:067630) Shareholders Should Be Cautious Despite Solid Earnings
May 21HLB Life Science Co., Ltd.'s (KOSDAQ:067630) 25% Share Price Surge Not Quite Adding Up
Mar 15HLB Life Science (KOSDAQ:067630) Has Debt But No Earnings; Should You Worry?
Apr 12Did You Participate In Any Of HLB Life Science's (KOSDAQ:067630) Incredible 442% Return?
Feb 14Is HLB Life Science (KOSDAQ:067630) A Risky Investment?
Jan 10We're Not So Sure You Should Rely on HLB Life Science's (KOSDAQ:067630) Statutory Earnings
Dec 06Financial Position Analysis
Short Term Liabilities: A067630's short term assets (₩95.6B) exceed its short term liabilities (₩67.9B).
Long Term Liabilities: A067630's short term assets (₩95.6B) exceed its long term liabilities (₩66.4B).
Debt to Equity History and Analysis
Debt Level: A067630's net debt to equity ratio (13%) is considered satisfactory.
Reducing Debt: A067630's debt to equity ratio has increased from 16.9% to 33% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: A067630 has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: A067630 has sufficient cash runway for 1.5 years if free cash flow continues to reduce at historical rates of 14.7% each year.